S-1/A: Curanex Pharmaceuticals Files S-1/A for IPO to Fund Botanical Drug Development, Extends Key Promissory Note

Curanex Pharmaceuticals Inc., a developmental stage company focused on botanical drugs for inflammatory diseases, has filed an S-1/A amendment for its initial public offering to raise up to $15 million, while also extending the maturity date of a significant related-party promissory note.

Summary

• Curanex Pharmaceuticals Inc. is a developmental stage company focused on discovering, developing, and commercializing innovative botanical drugs for inflammatory diseases, with its lead candidate, Phyto-N, currently in early preclinical development.
• The company is pursuing an Initial Public Offering (IPO) of 3,750,000 shares of common stock, with an expected initial public offering price between US$4.00 and US$6.00 per share, aiming to raise approximately $12,114,369 in net proceeds (or $14,206,869 if the over-allotment option is fully exercised).
• Proceeds from the IPO are intended to fund FDA-required GLP toxicology and pharmacokinetic studies ($2,000,000), manufacture clinical trial material ($1,000,000), and initiate Phase I ($3,000,000) and Phase II ($4,000,000) clinical trials for Phyto-N in ulcerative colitis, with the remaining $2,114,369 for working capital.
• The full business plan through FDA approval and product launch is estimated to require over $150 million, with the first phase (through initiating Phase II for ulcerative colitis) estimated at approximately $12 million over 18-24 months.
• The company reported a net loss of $(137,583) for the three months ended March 31, 2025, and $(361,506) for the fiscal year ended December 31, 2024, with no revenue generated in these periods.
• Cash and cash equivalents totaled $198,943 as of March 31, 2025, an increase from $148,891 as of December 31, 2024, primarily due to a $200,000 shareholder loan received in February 2025.
• A $200,000 promissory note issued to Dian Ying Jing (founder, Secretary, and CEO's wife) on February 4, 2025, with a maturity date of February 4, 2026, was amended on May 30, 2025, to extend its maturity to February 4, 2027.
• Another $200,000 loan was received from Dian Ying Jing on May 21, 2025, with a new promissory note issued on May 23, 2025, maturing on May 23, 2027.
• The company underwent a reincorporation from New York to Nevada on June 10, 2024, and completed a 3-for-5 reverse stock split on November 19, 2024.
• Curanex acquired four provisional patent applications (now expired, with three converted into an international PCT application filed March 13, 2025) and eight R&D animal study reports from Duraviva Pharma Inc., a related party, on June 17, 2024, for $730,000 cash and 23,400,000 shares of common stock.
• Founders and their immediate family beneficially own approximately 80.0% of outstanding common stock and 100% of Series A Preferred Stock (40% voting power), which will be approximately 69.3% of voting stock post-IPO.

Sentiment

Score: 3

Explanation: The company is in a very early preclinical stage with no revenue and significant accumulated losses, requiring substantial future capital. While preclinical data for its lead candidate, Phyto-N, is promising across multiple indications, and management has relevant experience, the high risks associated with botanical drug development, intellectual property challenges, and the long, uncertain path to regulatory approval and commercialization warrant a cautious outlook.

Positives

• Phyto-N, the lead drug candidate, has shown positive results in preclinical animal models for multiple inflammatory diseases including ulcerative colitis, atopic dermatitis, COVID-19, diabetes, NAFLD, and gout.
• Phyto-N has a long history of human use in Chinese traditional medicine (over 30 years), which may provide encouraging insights for its clinical development.
• Preliminary safety studies in animals have shown Phyto-N does not exhibit toxicity or side effects at tested doses.
• The company has a clear initial business plan to submit an Investigational New Drug (IND) application for ulcerative colitis in the first half of 2026 and proceed to Phase I and II trials.
• The management team possesses extensive experience in pharmaceutical investment, R&D, drug discovery, development, and commercialization, including expertise in botanical medicine and US regulatory strategy.
• The company has established a proprietary platform for identifying, extracting, and optimizing novel anti-inflammatory compounds from medicinal plants.
• Recent shareholder loans totaling $400,000 demonstrate continued financial support from key insiders, strengthening the cash position to $198,943 as of March 31, 2025.
• The company has established a robust corporate governance framework with independent directors and dedicated audit, compensation, and nominating committees.

Negatives

• The company has a very limited operating history and has not generated any revenue since discontinuing health and dietary supplemental products in 2023.
• Curanex reported recurring net losses, with $(137,583) for Q1 2025 and $(361,506) for FY 2024, and negative cash flows from operating activities.
• The lead product candidate, Phyto-N, is still in early preclinical development, requiring significant further clinical development and investment before potential commercialization.
• The company estimates needing over $150 million to execute its full business plan through FDA approval and product launch, with no assurance of securing this additional funding.
• All four provisional patent applications related to Phyto-N expired on March 18, 2025, and there is no assurance that the filed international PCT application will result in a registered utility patent in the U.S. or broader international protection.
• The development and approval process for botanical drugs involves unique challenges and regulatory considerations, with only two botanical drugs having received FDA approval to date, indicating a higher risk of delays or rejections.
• The company is heavily dependent on the success of Phyto-N, and any failure in its clinical trials could significantly impair commercial prospects and potentially lead to cessation or reduction of operations.
• The company relies on third parties for manufacturing clinical drug supplies, which introduces risks related to regulatory compliance, quality assurance, and potential delays or supply shortfalls.
• The initial public offering price range of $4.00-$6.00 per share is substantially higher than the pro forma as adjusted net tangible book value of $0.4497 per share, resulting in immediate and substantial dilution of $3.5503 per share for new investors.
• Founders and their immediate family will continue to own approximately 69.3% of the voting stock post-IPO, allowing them to exert significant control over company decisions, which may not always align with other shareholders' interests.

Risks

• Limited operating history in an evolving industry makes future prospects difficult to evaluate and increases the risk of failure.
• Failure to raise additional capital when needed would have a material adverse effect on business, financial condition, and results of operations, potentially requiring reduction or discontinuation of operations.
• As a developmental stage pharmaceutical company with no commercial products, significant clinical development and investment are required before revenue generation.
• The company expects to incur further losses and has negative cash flows from operating activities, dependent on future equity or other financing.
• High costs of maintaining public company reporting requirements (estimated over $100,000 per year) may preclude acceptable financing terms.
• Inability to obtain patent protection for Phyto-N or successfully develop and commercialize it would significantly diminish future operations.
• Clinical trials have a high risk of failure, and results of earlier studies may not be predictive of future outcomes, potentially impairing commercial prospects.
• Failure to obtain and maintain effective registration of non-provisional utility patents in the United States will have a significant adverse effect on the business.
• Claims by other companies of intellectual property infringement may result in liability for damages or stop development and commercialization efforts.
• Reliance on third parties for manufacturing clinical drug supplies exposes the company to risks of breach, termination, or nonrenewal of agreements, and potential supply delays or quality issues.
• Inability to attract, retain, and motivate well-qualified employees could harm the business.
• Potential involvement in various legal proceedings, including intellectual property litigation, could result in substantial costs and diversion of management attention.
• The regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time-consuming, and inherently unpredictable, with no assurance of approval for product candidates.
• The development and approval process for botanical drugs involves unique challenges (complex nature, standardization, pharmacokinetics, manufacturing complexities) that may result in additional costs, delays, or failure to obtain regulatory approval.
• Substantial delays in clinical studies or failure to demonstrate safety and efficacy to regulatory authorities could occur at any stage.
• Compliance with corporate governance laws and financial reporting standards, including cybersecurity and data leakage risks, poses ongoing challenges and costs.
• Geopolitical conditions, including trade disputes and acts of war or terrorism, could adversely affect operations and financial results.
• Inflation may adversely affect operations and financial results by increasing costs of raw materials, components, and labor.
• There is no active public trading market for common stock, and no assurance that one will develop, making it difficult to liquidate shares quickly.
• The price of common stock may rapidly fluctuate or decline regardless of operating performance, leading to substantial losses for investors.
• A possible short squeeze due to sudden demand largely exceeding supply may lead to price volatility.
• Future sales of common stock or the perception of such sales may depress share price, and additional capital raises may dilute ownership.
• Founders will continue to own a significant percentage of voting stock, enabling them to exert significant control over matters subject to shareholder approval.
• Being a public company increases legal and financial compliance costs and diverts management attention.
• Failure to satisfy Nasdaq listing requirements could result in delisting, impairing stockholders' ability to trade shares and the company's ability to raise capital.
• Failure to maintain effective internal controls over financial reporting could adversely impact public disclosures and stock price.
• As an emerging growth company, reduced disclosure requirements may make common stock less attractive to investors.
• As a controlled company, the company may choose to exempt itself from certain corporate governance requirements, potentially reducing protection for public shareholders.

Future Outlook

Curanex Pharmaceuticals plans to advance its lead product candidate, Phyto-N, into clinical development, with an Investigational New Drug (IND) application for ulcerative colitis targeted for submission in the first half of 2026. Following successful Phase I trials, the company intends to proceed with Phase II trials for ulcerative colitis as its lead indication. Contingent on trial success and funding, additional Phase II trials in other high-value indications such as atopic dermatitis, COVID-19, gout, diabetes, and NAFLD may be initiated. The long-term vision is to maximize Phyto-N's value and build a robust pipeline of botanical drug candidates, aiming for FDA approval and commercialization, though the process is uncertain and subject to funding availability.

Management Comments

• Jun Liu, Chief Executive Officer and President, has three decades of real estate development experience and over twenty years in pharmaceutical investment and research, including leadership roles in botanical and chemical drugs.
• Dian Ying Jing, Secretary and a founder, previously served as CEO and President, overseeing financial operations and strategic leadership.
• Haiyan Yang, Chief Financial Officer and Treasurer, is a Certified Public Accountant with over 17 years of experience in finance and business management, including IPO readiness and capital structure optimization.
• Huijuan Zhong, Chief Science Officer, has over 23 years of pharmaceutical industry experience in drug substance and product development, from preclinical to NDA filings.
• Liqin Xie, Chief Operating Officer, has over 15 years of experience in drug discovery and development across big pharma and biotech, with expertise in IBD in vivo pharmacology and IND filing.
• Ning Zhang, Chief Technology Officer, has extensive experience in traditional Chinese medicine, focusing on extraction and identification of active pharmaceutical ingredients and enhancing dosage forms.
• The company's founders and related research personnel have been devoted to natural substances (phytomedicine) since 1996, developing a proprietary platform for identifying, extracting, and optimizing novel anti-inflammatory compounds.

Industry Context

The global market for inflammatory disease treatments is rapidly growing, valued at approximately $26.7 billion in 2023 and projected to reach $50 billion by 2034, driven by increasing prevalence and unmet medical needs. The botanical and plant-derived drugs market is also expanding rapidly, reaching approximately $34 billion USD, as consumer preferences shift towards natural health solutions. While traditional anti-inflammatory drugs often have limited efficacy and severe side effects, botanical drugs with multi-target mechanisms represent a promising frontier. However, the regulatory landscape for botanical drugs is challenging, with only two such drugs (Veregen and Fulyzaq/Mytesi) having received FDA approval to date, highlighting the innovative yet difficult nature of this approach.

Comparison to Industry Standards

• Curanex's lead candidate, Phyto-N, is a botanical drug, a category with limited FDA approvals (only two to date: Veregen and Fulyzaq/Mytesi), indicating a more complex and potentially longer regulatory pathway compared to conventional single-molecule drugs.
• Unlike targeted biologics such as Dupilumab (Dupixent) for atopic dermatitis, which focus on specific receptors (e.g., IL-4R), Phyto-N is positioned as a multi-target botanical extract, potentially offering a broader therapeutic effect, though this requires confirmation in human clinical trials.
• In the NAFLD treatment market, the recent FDA approval of Rezdiffra (resmetirom) by Madrigal Pharmaceuticals on March 14, 2024, sets a new benchmark for NASH therapies, which Phyto-N, if approved, would compete against. Rezdiffra has known side effects like diarrhea and nausea, and interactions with statins, which Phyto-N aims to potentially improve upon with a favorable tolerability profile.
• The gout treatment market includes established therapies like Febuxostat, which carries an FDA black box warning for cardiovascular risk. Phyto-N's preclinical data suggests it may reduce inflammatory mediators and improve renal function, potentially offering an alternative with a different safety profile, but this needs to be validated in human trials.
• Major pharmaceutical competitors in inflammatory diseases, such as AbbVie, Janssen Biotech, Takeda Pharmaceutical, Pfizer, Merck, Novartis, and Boehringer Ingelheim, possess significantly greater marketing and research capabilities, posing a substantial competitive challenge for Curanex.
• The company's preclinical studies for Phyto-N in ulcerative colitis, atopic dermatitis, COVID-19, diabetes, NAFLD, and gout, conducted at institutions like Rutgers University and Chinese Academy of Medical Sciences, provide initial evidence, but these are early-stage findings and do not guarantee translation to human efficacy or safety, a common hurdle in drug development.

Management Changes

Corporate Governance

Legal Proceedings

• No legal, governmental, or regulatory investigations, actions, demands, claims, suits, arbitrations, inquiries, or proceedings are pending or threatened that would, individually or in the aggregate, have a Material Adverse Effect on the company.
• The company may become a party to various legal proceedings in the ordinary course of business, including commercial, employment, and other litigation and claims, as well as governmental and other regulatory investigations and proceedings.
• Patent and other intellectual property litigation may be protracted and expensive, and the results are difficult to predict, potentially requiring the company to stop offering certain features, purchase licenses, or modify products.

Related Party Transactions

• On June 17, 2024, the company entered into an Asset Purchase Agreement with Duraviva Pharma Inc., a related entity where the company's CEO, President, and his immediate family (including the Secretary) are also majority shareholders, officers, and directors.
• Under the Asset Purchase Agreement, Duraviva transferred four provisional patent applications (now expired) and eight R&D animal study reports to Curanex for $730,000 cash and 23,400,000 shares of common stock.
• On February 4, 2025, the company received a $200,000 loan from Dian Ying Jing (founder, Secretary, and wife of CEO Jun Liu), evidenced by a promissory note with an interest rate of 4.34% per annum, originally due February 4, 2026.
• On May 30, 2025, Amendment No. 1 to the February 4, 2025, promissory note was executed, extending its maturity date to February 4, 2027.
• On May 21, 2025, Dian Ying Jing loaned an additional $200,000 to the company, evidenced by a new promissory note issued on May 23, 2025, with an interest rate of 4.34% per annum, due May 23, 2027.
• In January 2025, the company assumed an office lease from Duraviva, a related party under common control, with the lease extending through August 31, 2026.

Stakeholder Impact

• Shareholders: Will experience immediate and substantial dilution (approx. $3.55 per share) from the IPO. Existing shareholders will retain significant control (approx. 86.49% post-IPO without over-allotment, 69.3% voting power for founders). Future equity offerings could lead to further dilution. Investment return is primarily dependent on stock price appreciation, as no dividends are anticipated.
• Employees: The company plans to adopt an equity compensation plan immediately after the IPO, setting aside 15% of outstanding share capital for key management and staff, which could attract and retain talent.
• Customers/Patients: Potential for new treatment options for inflammatory diseases if Phyto-N successfully navigates clinical trials and regulatory approval, addressing unmet medical needs.
• Creditors: The company relies on external funding and shareholder support to fund operations, with existing shareholder loans extended, indicating ongoing dependence on these relationships.
• Regulatory Bodies: The company is subject to extensive regulation by the FDA and comparable foreign authorities, requiring rigorous evidence of safety and efficacy for botanical drugs, which may involve additional costs and delays.

Next Steps

• Submit an Investigational New Drug (IND) application for ulcerative colitis in the first half of 2026.
• Initiate and conduct Phase I clinical trials for Phyto-N in ulcerative colitis 30 days post-IND submission, if allowed by the FDA.
• Proceed with Phase II trials for ulcerative colitis if Phase I results are positive.
• Potentially initiate additional Phase II trials in other high-value indications (atopic dermatitis, COVID-19, gout, diabetes, NAFLD) contingent on ulcerative colitis trial success and funding.
• Continue to invest in translational research to elucidate mechanisms of action, biomarkers, and patient stratification strategies for Phyto-N.
• Identify and isolate active chemical compounds from Phyto-N for potential development of novel small molecule drugs.
• Seek strategic partnerships for co-development, co-promotion, or out-licensing of drug candidates.
• Pursue non-dilutive funding opportunities such as research grants and contracts.
• Establish manufacturing, supply chain, and distribution capabilities for commercialization upon regulatory approval.
• Complete FDA-required GLP toxicology and pharmacokinetic studies for Phyto-N.
• Manufacture clinical trial material for Phyto-N.

Key Dates

Keywords

Pharmaceuticals, Botanical Drugs, Inflammatory Diseases, Phyto-N, Ulcerative Colitis, Atopic Dermatitis, COVID-19 Treatment, Diabetes Treatment, NAFLD Treatment, Gout Treatment, Preclinical Development, Clinical Trials, FDA Approval, IND Application, IPO, Nasdaq Listing, SEC Filing, S-1/A, Biotechnology, Drug Discovery, Intellectual Property, Shareholder Loan, Reverse Stock Split, Controlled Company